Drug Trial Radar · NCT05407636
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
735
Actual
Start
Jan 13, 2022
Primary completion
Oct 2026
Study completion Nov 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- REGENXBIO Inc.
- First posted
- Jun 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to 12 weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. ABBV-RGX-314 is being developed as a potential one-time treatment for wet AMD.
Conditions
- AMD
- nAMD
- Wet Age-related Macular Degeneration
- wAMD
- WetAMD
- CNV
Interventions
ABBV-RGX-314 Dose 1Genetic
AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
ABBV-RGX-314 Dose 2Genetic
AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
Aflibercept (EYLEA®)Biological
2.0 mg (0.05 mLsolution) administered by intravitreal injection approximately every 8 weeks after 3 monthly injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in Best Corrected Visual Acuity (BCVA)Time frame: At Week 54
- Bilateral Treatment Substudy: Incidence of ocular AEs and any SAEsTime frame: Week 50
Locations
181 sites in 10 countries. Site status is shown where the registry gives one.
Barnet Dulaney Eye Center-Phoenix /ID# 256340
Phoenix, Arizona
Retinal Research Institute /ID# 256238
Phoenix, Arizona
Retina Macula Institute of Arizona /ID# 271026
Scottsdale, Arizona
California Retina Consultants - Bakersfield /ID# 256240
Bakersfield, California
Retina Vitreous Assoc Med Grp /ID# 256246
Beverly Hills, California
Retinal Diagnostic Center /ID# 256262
Campbell, California
The Retina Partners - Encino /ID# 259660
Encino, California
Retina Consultants of Orange County /ID# 256267
Fullerton, California
Jacobs Retina Center at UCSD/ID# 256320
La Jolla, California
California Retina Consultants - Oxnard - North Ventura Road /ID# 262883
Oxnard, California
Byers Eye Institute Stanford /ID# 262853
Palo Alto, California
Retina Consultants of San Diego /ID# 256258
Poway, California
Kaiser Permanente - Riverside Medical Center /ID# 262413
Riverside, California
UC Davis Health Eye Center
Sacramento, California
Retinal Consultants Medical Group, Inc. - Greenback /ID# 256353
Sacramento, California
Orange County Retina Medical Group /ID# 256286
Santa Ana, California
Macula Retina Vitreous Center - Torrance /ID# 270247
Torrance, California
Bay Area Retina Associates - Walnut Creek - Lennon Lane /ID# 268513
Walnut Creek, California
Retina Consultants of Southern Colorado /ID# 256285
Colorado Springs, Colorado
Southwest Retina Research Center /ID# 256261
Durango, Colorado
Colorado Retina Associates /ID# 256378
Lakewood, Colorado
Advanced Vision Research Institute /ID# 256380
Longmont, Colorado
Retina Consultants, P.C. /ID# 273610
Manchester, Connecticut
Rand Eye Institute /ID# 256337
Deerfield Beach, Florida
National Ophthalmic Research Institute /ID# 256344
Fort Myers, Florida
Vitreoretinal Associates, P.A. /ID# 256266
Gainesville, Florida
Florida Retina Consultants /ID# 256321
Lakeland, Florida
Florida Retina Institute - Orlando /ID# 256373
Orlando, Florida
Retina Specialty Institute /ID# 256268
Pensacola, Florida
Fort Lauderdale Eye Institute /ID# 266011
Plantation, Florida
Retina Vitreous Associates of Florida - St. Petersburg /ID# 256279
St. Petersburg, Florida
Center for Retina and Macular Disease /ID# 256335
Winter Haven, Florida
Georgia Retina - Marietta /ID# 256264
Marietta, Georgia
Retina Consultants of Hawaii /ID# 256278
‘Aiea, Hawaii
Northwestern Memorial Hospital - Department of Ophthalmology /ID# 256379
Chicago, Illinois
University Retina and Macula Associates /ID# 256288
Lemont, Illinois
University Retina and Macula Associates /ID# 256287
Oak Forest, Illinois
Illinois Retina Associates - Oak Park /ID# 256375
Oak Park, Illinois
Springfield Clinic - First /ID# 256371
Springfield, Illinois
Retina Partners Midwest, PC /ID# 256277
Indianapolis, Indiana
Showing 40 of 181 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.